Malhotra points out that studies have repeatedly shown CPAP fails to improve cardiovascular morbidity and mortality, so treating the underlying cause of the sleep apnea might be required to really see the benefits. Malhotra says, Everything went in the right direction
The figure 25.3 % surpasses: Tirzepatide SURMOUNT-1: 22.5 % Semaglutide STEP-1: 14.9 % Retatrutide Phase 2: 24.2 % (comparable, but Phase 3 results for Retatrutide are still lacking) It raises the question whether CagriSema will be the first molecule with an effect truly comparable to bariatric surgery (typically 2530 % reduction)
You deserve a weight management plan that feels right, works well, and helps you achieve the results you want
Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment
Abstract Accumulating evidence supports the early use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose transporter-2 inhibitors (SGLT-2is) for the treatment of type 2 diabetes
Pharmacology and clinical development of GIP/GLP-1/glucagon triple agonists